Arrowstreet Capital
SPRY icon

Arrowstreet Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Arrowstreet Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,967
Closed -$127K – 1865
2024
Q2 		$127K Sell
14,967
-65,831
-81% -$584K ﹤0.01% 1464
2024
Q1 		$826K Buy
+80,798
New +$602K ﹤0.01% 1361

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Arrowstreet Capital's SPRY Position: Q3 2024 in Review

Arrowstreet Capital sold out of ARS Pharmaceuticals (SPRY) in Q3 2024, closing a stake of 14,967 shares — an estimated $127K sold.

Arrowstreet Capital first reported a position in SPRY in Q1 2024 and held it in 2 quarters. The position peaked at $826K in Q1 2024. 150 funds tracked by Wall St. Rank hold SPRY as of Q3 2024.

  • Arrowstreet Capital reported no remaining ARS Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Arrowstreet Capital sold 14,967 ARS Pharmaceuticals shares in Q3 2024, an estimated $127K.
  • Arrowstreet Capital first reported a position in ARS Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Arrowstreet Capital's ARS Pharmaceuticals position peaked at $826K in Q1 2024.
  • 150 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2024.

Based on Arrowstreet Capital's 13F filing for Q3 2024, filed 14 Nov 2024.